Gene therapy could ‘turn off’ severe allergies
A single treatment giving life-long protection from severe allergies such as asthma could be made possible by immunology research at The University of Queensland.
A team led by Associate Professor Ray Steptoe at the UQ Diamantina Institute has been able to ‘turn-off’ the immune response which causes allergic reaction in animals.
“When someone has an allergy or asthma flare-up, the symptoms they experience results from immune cells reacting to protein in the allergen,” Professor Steptoe said.
“The challenge in asthma and allergies is that these immune cells, known as T-cells, develop a form of immune ‘memory’ and become very resistant to treatments.
“We have now been able ‘wipe’ the memory of these T-cells in animals with gene therapy, de-sensitising the immune system so that it tolerates the protein.
“Our work used an experimental asthma allergen, but this research could be applied to treat those who have severe allergies to peanuts, bee venom, shell fish and other substances.”
Dr Steptoe said the findings would be subject to further pre-clinical investigation, with the next step being to replicate results using human cells in the laboratory.”
“We take blood stem cells, insert a gene which regulates the allergen protein and we put that into the recipient.
“Those engineered cells produce new blood cells that express the protein and target specific immune cells, ‘turning off’ the allergic response.”
Dr Steptoe said the eventual goal would be a single injected gene therapy, replacing short-term treatments that target allergy symptoms with varying degrees of effectiveness.
“We haven’t quite got it to the point where it’s as simple as getting a flu jab, so we are working on making it simpler and safer so it could be used across a wide cross-section of affected individuals,” Dr Steptoe said.
“At the moment, the target population might be those individuals who have severe asthma or potentially lethal food allergies.”
Dr Steptoe’s research has been funded by the Asthma Foundation and the National Health and Medical Research Council.
Asthma Foundation of Queensland and New South Wales Chief Executive Officer Dr Peter Anderson said more than two million Australians have asthma, and current statistics show that more than half of those are regularly burdened with symptoms of the disease.
“Even though there are effective treatments available for the vast majority, patients face a number of obstacles and challenges in their self-management practices,” Dr Anderson said.
“The Foundation welcomes the findings of this research and looks forward to a day in the future when a safe one-off treatment may be available that has the potential to eliminate any experience of asthma in vulnerable patients.”
Learn more: Gene therapy could ‘turn off’ severe allergies
The Latest on: Gene therapy for allergies
- Global Biologics Outsourcing Market Forecast to 2028: Focus on Discovery Services, Preclinical Development Services & Clinical Developmenton October 8, 2020 at 5:04 am
The "Biologics Outsourcing Global Market - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. The biologics outsourcing global market is expected to grow at low teen CAGR to ...
- Mustang Bio Licenses LentiBOOST™ Technology from SIRION Biotechon October 6, 2020 at 8:08 am
(GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO) and SIRION Biotech GmbH (“SIRION”) today announced a licensing agreement under which Mustang has acquired rights to SIRION’s ...
- Biologics Outsourcing Global Market - Forecast to 2028on October 2, 2020 at 1:16 am
Reportlinker.com announces the release of the report "Biologics Outsourcing Global Market - Forecast to 2028" - Biologics also include live attenuated microorganisms (vaccines), allergenic extracts ...
- The First Patient To Be Cured Of HIV Has Died Following A Cancer Relapseon October 1, 2020 at 7:39 am
Known as the “Berlin patient,” British-born Timothy Ray Brown became the first person in history to be cured of human immunodeficiency virus (HIV), the ill ...
- Mustang Bio Announces Orphan Drug Designation for MB-207 for the Treatment of X-linked Severe ...on September 22, 2020 at 5:00 am
(GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into ...
via Google News and Bing News